#recombinant-antivenom

Issues, solutions, and case studies for recombinant-antivenom

Found 4 nodes with this tag: 0 issues · 2 solutions · 2 case studies

Solutions 2

#00134Deploy repurposed small-molecule toxin inhibitors as broad-spectrum early therapy

Use varespladib (PLA2 inhibitor), marimastat (SVMP inhibitor), and DMPS/dimercaprol (Zn2+ chelators) as cheap, heat-stable, species-agnostic first-line treatment that buys time before or alongside antivenom, particularly in the pre-hospital window.

Case studies

#00131Replace animal-derived antivenom with broadly-neutralizing recombinant human antibody cocktails

Manufacture antivenom as a defined cocktail of recombinant human monoclonal antibodies targeting conserved toxin families (3FTx, PLA2, SVMP, SVSP), replacing dozens of narrow regional polyclonal sera with a small number of broad-spectrum products split roughly by neurotoxic-elapi

Case studies

Case studies 2

Puducherry, India (multi-site trial, with sites also in the USA)

Partial

Ophirex, Inc. (sponsor), with emergency-department sites in India and the USA · 2021–2022 · National

BRAVO was a double-blind, randomised, placebo-controlled phase II trial of oral varespladib-methyl plus standard care (including antivenom) versus standard care plus placebo, run in emergency departments in India (Puduc…

Patients randomised95patients

Snakebite Severity Score improvement vs placebo (overall)difference −0.4 (95% CI −0.8 to 0.1) → not significant (p=0.13)

1 source

South San Francisco, California, USA

Ongoing

Centivax, Inc.; Columbia University; NIAID (US National Institute of Allergy and Infectious Diseases) · Global

Researchers isolated broadly-neutralizing IgG antibodies from the memory B-cells of a human donor (Tim Friede) who had self-immunized with escalating venom doses from 16 lethal elapid species over ~18 years. Two antibod…

Elapid species with full protection (mouse model)13 of 19

Elapid species with partial protection (mouse model)6 of 19

2 sources

communityfix.org